Vesigen Therapeutics
Vision
Expanding the universe of druggable targets.
Approach
Vesigen Therapeutics is a biotechnology company advancing groundbreaking therapies directed to intracellular targets using a fusogenic extracellular vesicle delivery technology. Their patented technology, called ARMM, enables the delivery of a wide range of payloads, including RNAs, proteins, and gene-editing complexes (Cas9/gRNA) directly into the cytoplasm of target cells, expanding the universe of druggable targets. The team is committed to leveraging ARMMs technology to develop transformative medicines and address currently unmet medical needs.
Vesigen Therapeutics is addressing
CEO:
Paulash Mohsen
Founders:
Robert Millman
Quan Lu, PhD
First investment:
December 2019